BeyondSpring (BYSI) 6-K 30 Dec 21 Current report (foreign) Financial data

Document And Entity Information

Document And Entity Information	Sep. 30, 2021
Document Information [Line Items]
Entity Registrant Name	BeyondSpring Inc.
Document, Type	6-K
Document, Period End Date	Sep. 30, 2021
Current Fiscal Year End Date	--12-31
Entity, File Number	001-38024
Entity, Address, Address Line One	28 Liberty Street, 39th Floor
Entity, Address, City or Town	New York
Entity, Address, State or Province	NY
Entity, Address, Postal Zip Code	10005
Amendment Flag	false
Entity Central Index Key	0001677940

Audited Consolidated Balance Sh

Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021 - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 63,434	$ 109,537
Short-term investments	28,166	0
Advances to suppliers	1,762	3,505
Prepaid expenses and other current assets	1,306	358
Total current assets	94,668	113,400
Noncurrent assets:
Property and equipment, net	169	184
Operating lease right-of-use assets	2,164	2,174
Other noncurrent assets	1,368	1,280
Total noncurrent assets	3,701	3,638
Total assets	98,369	117,038
Current liabilities:
Accounts payable	2,128	2,216
Accrued expenses	7,187	5,607
Current portion of operating lease liabilities	390	787
Deferred revenue	1,532	1,350
Long-term loans, current portion	1,552	0
Other current liabilities	5,768	3,806
Total current liabilities	18,557	13,766
Noncurrent liabilities:
Long-term loans, noncurrent portion	0	2,167
Operating lease liabilities	1,623	1,359
Deferred revenue	37,769	7,925
Other noncurrent liabilities	1,259	0
Total noncurrent liabilities	40,651	11,451
Total liabilities	59,208	25,217
Commitments and contingencies
Mezzanine equity
Contingently redeemable noncontrolling interests	5,354	5,196
Equity
Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 39,141,913 and 39,142,253 shares issued and outstanding as of December 31, 2020 and September 30, 2021, respectively)	4	4
Additional paid-in capital	371,209	366,451
Accumulated deficit	(332,484)	(277,818)
Accumulated other comprehensive loss	(398)	(297)
Total BeyondSpring Inc.’s shareholders’ equity	38,331	88,340
Noncontrolling interests	(4,524)	(1,715)
Total equity	33,807	86,625
Total liabilities, mezzanine equity and equity	$ 98,369	$ 117,038

Audited Consolidated Balance _2

Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021 (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Ordinary shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares, authorized (in shares)	500,000,000	500,000,000
Ordinary shares, issued (in shares)	39,142,253	39,141,913
Ordinary shares, outstanding (in shares)	39,142,253	39,141,913

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2021 - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue	$ 337	$ 0	$ 1,013	$ 0
Operating expenses
Research and development	(8,459)	(8,637)	(31,102)	(33,369)
General and administrative	(10,227)	(6,710)	(25,659)	(12,227)
Loss from operations	(18,349)	(15,347)	(55,748)	(45,596)
Foreign exchange gain, net	38	174	82	109
Interest income	27	10	88	102
Interest expense	(20)	(21)	(66)	(63)
Other income	749	0	752	3
Loss before income tax	(17,555)	(15,184)	(54,892)	(45,445)
Income tax expenses	(2,588)	0	(2,588)	0
Net loss	(20,143)	(15,184)	(57,480)	(45,445)
Less: Net loss attributable to noncontrolling interests	(1,773)	(644)	(2,814)	(2,068)
Net loss attributable to BeyondSpring Inc.	$ (18,370)	$ (14,540)	$ (54,666)	$ (43,377)
Net loss per share
Basic and diluted (in dollars per share)	$ (0.47)	$ (0.48)	$ (1.40)	$ (1.51)
Weighted-average shares outstanding
Basic and diluted (in shares)	39,024,892	30,303,093	39,013,526	28,658,215
Other comprehensive loss, net of tax of nil:
Foreign currency translation adjustment loss	$ (41)	$ (277)	$ (116)	$ (226)
Comprehensive loss	(20,184)	(15,461)	(57,596)	(45,671)
Less: Comprehensive loss attributable to noncontrolling interests	(1,782)	(677)	(2,829)	(2,107)
Comprehensive loss attributable to BeyondSpring Inc.	$ (18,402)	$ (14,784)	$ (54,767)	$ (43,564)

Unaudited Interim Condensed C_2

Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2020 and 2021 - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (57,480)	$ (45,445)
Adjustments to reconcile net loss to cash used in operating activities:
Share-based compensation	5,290	6,082
Depreciation expenses	54	54
Non-cash operating lease expense	366	457
Loss on derecognition of right-of-use assets	22	0
Paycheck Protection Program Loan Forgiveness	(635)	0
Unrealized gain on short-term investments	(105)	0
Changes in assets and liabilities:
Short-term investments	(12,416)	0
Advances to suppliers	1,743	191
Prepaid expenses and other current assets	(948)	(75)
Other noncurrent assets	(88)	(234)
Accounts payable	(88)	(346)
Accrued expenses	1,618	2,519
Operating lease liabilities	(511)	(488)
Other current liabilities	1,792	502
Deferred revenue	30,026	0
Other noncurrent liabilities	1,036	0
Net cash used in operating activities	(30,324)	(36,783)
Cash flows from investing activities:
Acquisitions of property and equipment	(39)	(34)
Purchase of short-term investments	(15,645)	0
Net cash used in investing activities	(15,684)	(34)
Cash flows from financing activities:
Proceeds from issuance of ordinary shares, net of underwriting discounts and commissions	0	31,933
Proceeds from exercise of share options	83	0
Payments of offering costs	(44)	(594)
Payments of issuance costs of contingently redeemable noncontrolling interests	(38)	0
Proceeds from loans	0	635
Proceeds from related party borrowings	0	32
Repayment of related party borrowings	0	(61)
Net cash provided by financing activities	1	31,945
Effect of foreign exchange rate changes, net	(96)	(187)
Net decrease in cash and cash equivalents	(46,103)	(5,059)
Cash and cash equivalents at beginning of period	109,537	35,933
Cash and cash equivalents at end of period	63,434	30,874
Supplemental disclosures of cash flow information
Interest paid	71	60
Interest received	82	156
Non-cash activities:
Operating right-of-use assets obtained in exchange for operating lease liabilities	$ 378	$ 259

Note 1 - Nature of the Business

Note 1 - Nature of the Business and Basis of Preparation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of the business and basis of preparation BeyondSpring Inc. (the “Company”) was incorporated in the Cayman Islands on November 21, 2014. As of September 30, 2021, Percentage of Date of ownership by the Principal Name of company Place of incorporation incorporation Company Activities BeyondSpring Pharmaceuticals Inc. Delaware, (“BeyondSpring US ”) United States of America (“U.S.”) June 18, 2013 100% Clinical trial activities BeyondSpring Ltd. The British Virgin Islands (“BVI”) December 3, 2014 100% Holding company BeyondSpring (HK) Limited (“BeyondSpring HK”) Hong Kong January 13, 2015 100% Holding company Wanchun Biotechnology Limited (“BVI Biotech”) BVI April 1, 2015 100% Holding company Wanchun Biotechnology (Shenzhen) Ltd. The People’s Republic of China (“Wanchun Shenzhen”) (“PRC”) April 23, 2015 100% Holding company Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) PRC May 6, 2015 58.0% Clinical trial activities BeyondSpring Pharmaceuticals Australia PTY Ltd. (“BeyondSpring Australia”) Australia March 3, 2016 100% Clinical trial activities Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”) PRC May 21, 2018 58.0% Holding company SEED Therapeutics Inc. (“SEED”) BVI June 25, 2019 59.0% Pre-clinical development activities SEED Technology Limited (“SEED Technology”) BVI December 9, 2019 58.0% Holding company SEED Therapeutics US, Inc. (“SEED US”) Delaware, U.S. November 25, 2020 59.0% Pre-clinical development activities The accompanying unaudited interim condensed consolidated balance sheet as of September 30, 2021, three nine September 30, 2020 2021, nine September 30, 2020 2021, December 31, 2020. not In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for the three nine September 30, 2021 not 2021. December 31, 2020 not December 31, 2020.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of significant accounting policies Basis of consolidation The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. Going concern According to Accounting Standards Codification (“ASC”) 205 40, Presentation of Financial Statements - Going Concern 205 40” one not not 1 one 2 one The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has no product revenue and management expects accumulated losses to increase for the foreseeable future and has primarily funded these losses through equity financings. The Company incurred a net loss of $57,480 for the nine September 30, 2021 September 30, 2021. nine September 30, 2021. September 30, 2021, Based on the Company’s cash, cash equivalents and short-term investments on hand on September 30, 2021, not one Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include, but are not Short-term investments All liquid investments with an original maturity greater than three one The Company accounts for its investments in debt securities in accordance with ASC 320 10, Investments Debt Securities: Overall 320 10” 320 10. Debt securities that the Group has positive intent and ability to hold to maturity are classified as held-to-maturity securities and stated at amortized cost less allowance for credit losses. Debt securities that are bought and held primarily for the purpose of selling in the near term are classified as trading securities. Trading securities are recorded at fair value. Changes in unrealized gains and losses are recorded through earnings each period as part of other income. For the three nine September 30, 2021, Debt securities not September 30, 2021, The Company regularly evaluates its investments in debt securities for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net loss. No impairment losses or allowance for credit losses on investments were recorded for the periods presented. Revenue recognition Under ASC 606, Revenue from Contracts with Customers 606” 606, five five Once a contract is determined to be within the scope of ASC 606 The Company recognizes a contract asset or a contract liability in the consolidated balance sheets, depending on the relationship between the entity’s performance and the customer’s payment. Contract liabilities represent the excess of payments received as compared to the consideration, which are recorded as "Deferred revenue" on the consolidated balance sheets. The Company had no contract assets for the periods presented. Collaboration revenue At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements 808” 808 first 808 606. 808, In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of the agreements, the Company performs the five 606 The collaborative arrangements may one not Licenses of Intellectual Property: not Research and Development Service: Milestone Payments: not not Royalties: Fair value measurements The Company applies ASC 820, Fair Value Measurements and Disclosures 820” 820 ASC 820 three • Level 1—Observable • Level 2—Other • Level 3—Unobservable no ASC 820 three 1 2 3 Financial instruments of the Company primarily include cash and cash equivalents, short-term investments, accounts payable, contingently redeemable noncontrolling interests, forward liability and loans. The contingently redeemable noncontrolling interests were initially recorded at issuance price net of issuance costs. The Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying value of the contingently redeemable noncontrolling interests to equal the redemption value at the end of each reporting period. The Company measures its available-for-sale debt securities, trading debt securities and forward liability at fair value on a recurring basis. As of December 31, 2020 September 30, 2021, As of December 31, 2020, 2 Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 September 30, 2021 Fair value measurement Recurring fair value measurement Total Fair Value Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total gains $ $ $ $ $ As of December 31, 2020 (audited) Liabilities: Forward liability (Note 3) 278 - - 278 - As of September 30, 2021 (unaudited) Assets: Available-for-sale debt securities 1,645 - 1,645 - - Trading debt securities 12,521 - 12,521 - 105 Total assets measured at fair value 14,166 - 14,166 - 105 Liabilities Forward liability (Note 3) 278 - - 278 - Total liabilities measured at fair value 278 - - 278 - The Company determined the fair value of the forward liability with the assistance of an independent third December 31, 2020 September 30, 2021 three nine September 30, 2021, not The following table represents the assumptions used to estimate the fair value of the forward liability: Valuation technique Unobservable inputs Range Forward liability Discounted cash flow Fair value of underlying security 2.65 The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Forward liability $ Balance as of December 31, 2020 (audited) 278 Gains or losses from changes in fair value - Balance as of September 30, 2021 (unaudited) 278

Note 3 - Collaboration Revenue

Note 3 - Collaboration Revenue	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Collaboration Revenue Disclosure [Text Block]	3. Collaboration revenue Eli Lilly and Company On November 12, 2020, no three Under the Lilly Collaboration Agreement, Lilly paid SEED an upfront non-refundable fee of $10,000 in November 2020. 808, 606. Under ASC 606, not three 7 not In connection with the Lilly Collaboration Agreement, the Company and SEED Technology (collectively, the “BYSI Entities”) transferred certain contracts, know-how, materials and equipment, and documents related to a proprietary technology platform to SEED for 9,631,941 Series A- 1 1 1 2 2 1 2 15 “A2 2 November 12, 2022, A2 2 third 2 2 The Company recognized collaboration revenue of $337 and $1,013 related to the Lilly Collaboration Agreement for the three nine September 30, 2021, Jiangsu Hengrui Pharmaceuticals Co., Ltd. On August 25, 2021, September 22, 2021, may 2 nd /3 rd 50% Under the Hengrui Collaboration Agreement, Hengrui paid Wanchunbulin an upfront non-refundable fee of $31,039 ( RMB200,000 September 2021. RMB700,000 RMB400,000 The Hengrui Collaboration Agreement is within the scope of ASC 808 606, not 606. The Company determined that the license of exclusive commercialization rights of the Plinabulin Products (the “License”) and the manufacturing and supply of the Plinabulin Products (the “Manufacturing and Supply Services”) are not not not three nine September 30, 2021,

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and equipment, net Property and equipment consist of the following: December 31, 2020 September 30, 2021 $ $ (Unaudited) Office equipment 181 213 Laboratory equipment 121 127 Motor vehicles 24 24 Leasehold improvements 116 117 442 481 Less: accumulated depreciation (258 ) (312 ) Property and equipment, net 184 169 Depreciation expenses for the three nine September 30, 2020 three nine September 30, 2021

Note 5 - Loans

Note 5 - Loans	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Long-term Debt [Text Block]	5. Loans On March 28, 2019, three RMB10,000 September 30, 2021. March 28, 2022. On May 3, 2020, two May 3, 2022. July 2021, The aggregate contractual maturities of all borrowings due subsequent to September 30, 2021 Maturity dates Amount $ (Unaudited) Year ending December 31, 2021 - Year ending December 31, 2022 1,552 Total 1,552

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6. Related party transactions During the nine September 30, 2020, 60 RMB230 September 2020.

Note 7 - Income Taxes

Note 7 - Income Taxes	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7. Income taxes The income tax expenses for three nine September 30, 2021 $2,588 nil three nine September 30, 2020. nil nine September 30, 2020 2021, September 2021 Because the Company and its subsidiaries were in a cumulative loss position, and no There were no three nine September 30, 2021. not 12

Note 8 - Equity

Note 8 - Equity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Equity The movement of equity is as follows: BeyondSpring Inc. s shareholders Accumulated Additional other Non Ordinary share paid-in Accumulated comprehensive controlling Total Shares Amount capital deficit (loss) gain Subtotal interests equity $ $ $ $ $ $ $ Balances at January 1, 2021 (audited) 39,141,913 4 366,451 (277,818 ) (297 ) 88,340 (1,715 ) 86,625 Share-based compensation 12,248 - 5,143 - - 5,143 20 5,163 Forfeited restricted shares (40,679 ) - (310 ) - - (310 ) - (310 ) Exercise of options 28,771 - 83 - - 83 - 83 Accretion of contingently redeemable noncontrolling interest - - (158 ) - - (158 ) - (158 ) Foreign currency translation adjustment loss - - - - (101 ) (101 ) (15 ) (116 ) Net loss - - - (54,666 ) - (54,666 ) (2,814 ) (57,480 ) Balances at September 30, 2021 (unaudited) 39,142,253 4 371,209 (332,484 ) (398 ) 38,331 (4,524 ) 33,807 Balances at January 1, 2020 (audited) 27,885,613 3 246,979 (216,845 ) 140 30,277 854 31,131 Issuance of ordinary shares 2,613,590 - 31,395 - - 31,395 - 31,395 Share-based compensation 17,198 - 5,936 - - 5,936 132 6,068 Foreign currency translation adjustment loss - - - - (187 ) (187 ) (39 ) (226 ) Net loss - - - (43,377 ) - (43,377 ) (2,068 ) (45,445 ) Balances at September 30, 2020 (unaudited) 30,516,401 3 284,310 (260,222 ) (47 ) 24,044 (1,121 ) 22,923

Note 9 - Restricted Net Assets

Note 9 - Restricted Net Assets	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Restricted Assets Disclosure [Text Block]	9. Restricted net asset As a result of PRC laws and regulations, the Company’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. As of December 31, 2020 September 30, 2021, nil.

Note 10 - Employee Defined Cont

Note 10 - Employee Defined Contribution Plan	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	10. Employee defined contribution plan Full time employees of the Company in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company’s PRC subsidiaries make contributions to the government for these benefits based on certain percentages of the employees’ salaries. The Company has no three nine September 30, 2020 three nine September 30, 2021,

Note 11 - Net Loss Per Share

Note 11 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	11. Net loss per share Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows: Three months ended September 30, Nine months ended September 30, 2020 2021 2020 2021 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Numerator: Net loss attributable to BeyondSpring Inc.—basic and diluted $ (14,540 ) $ (18,370 ) $ (43,377 ) $ (54,666 ) Denominator: Weighted average number of ordinary shares outstanding—basic and diluted 30,303,093 39,024,892 28,658,215 39,013,526 Net loss per share —basic and diluted $ (0.48 ) $ (0.47 ) $ (1.51 ) $ (1.40 ) The effects of unvested restricted shares and share options were excluded from the calculation of diluted loss per share as their effect would have been anti-dilutive during the three nine September 30, 2020 2021.

Note 12 - Supplemental Balance

Note 12 - Supplemental Balance Sheet Information	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	12. Supplemental balance sheet information Other current liabilities consist of the following: As of December 31, As of September 30, 2020 2021 $ $ (Unaudited) Compensation related 2,222 2,376 Professional services 373 99 Income tax payable - 2,588 Other taxes related 857 358 Forward liability 278 278 Others 76 69 Total 3,806 5,768

Note 13 - Share-based Compensat

Note 13 - Share-based Compensation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	13. Share-based compensation The Company granted a total of 153,000 and 1,054,499 share options, and 6,699 and 8,125 restricted shares, respectively, for the three nine September 30, 2021. The following table summarizes total share-based compensation expense recognized for the three nine September 30, 2020 2021: Three months ended September 30, Nine months ended September 30, 2020 2021 2020 2021 $ $ $ $ (Unaudited) (Unaudited) (Unaudited) (Unaudited) Research and development 257 732 4,008 1,639 General and administrative 1,519 1,010 2,074 3,651 Total 1,776 1,742 6,082 5,290

Note 14 - Contingently Redeemab

Note 14 - Contingently Redeemable Noncontrolling Interests	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	14. Contingently redeemable noncontrolling interests The Company determined that Series A- 2 may 2 not The holder of the Series A- 2 2 2 not not 2 not not no No 2 third The Company recorded accretion of $96 and $158 for the three nine September 30, 2021. nine September 30, 2021 Contingently redeemable noncontrolling interests $ Balance as of December 31, 2020 (audited) 5,196 Accretion to redemption value 158 Balance as of September 30, 2021 (unaudited) 5,354

Note 15 - Commitments and Conti

Note 15 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	15. Commitments and contingencies Legal Proceedings From time to time, the Company may not

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of consolidation The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.
Going Concern, Policy [Policy Text Block]	Going concern According to Accounting Standards Codification (“ASC”) 205 40, Presentation of Financial Statements - Going Concern 205 40” one not not 1 one 2 one The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has no product revenue and management expects accumulated losses to increase for the foreseeable future and has primarily funded these losses through equity financings. The Company incurred a net loss of $57,480 for the nine September 30, 2021 September 30, 2021. nine September 30, 2021. September 30, 2021, Based on the Company’s cash, cash equivalents and short-term investments on hand on September 30, 2021, not one
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include, but are not
Investment, Policy [Policy Text Block]	Short-term investments All liquid investments with an original maturity greater than three one The Company accounts for its investments in debt securities in accordance with ASC 320 10, Investments Debt Securities: Overall 320 10” 320 10. Debt securities that the Group has positive intent and ability to hold to maturity are classified as held-to-maturity securities and stated at amortized cost less allowance for credit losses. Debt securities that are bought and held primarily for the purpose of selling in the near term are classified as trading securities. Trading securities are recorded at fair value. Changes in unrealized gains and losses are recorded through earnings each period as part of other income. For the three nine September 30, 2021, Debt securities not September 30, 2021, The Company regularly evaluates its investments in debt securities for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net loss. No impairment losses or allowance for credit losses on investments were recorded for the periods presented.
Revenue [Policy Text Block]	Revenue recognition Under ASC 606, Revenue from Contracts with Customers 606” 606, five five Once a contract is determined to be within the scope of ASC 606 The Company recognizes a contract asset or a contract liability in the consolidated balance sheets, depending on the relationship between the entity’s performance and the customer’s payment. Contract liabilities represent the excess of payments received as compared to the consideration, which are recorded as "Deferred revenue" on the consolidated balance sheets. The Company had no contract assets for the periods presented. Collaboration revenue At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements 808” 808 first 808 606. 808, In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of the agreements, the Company performs the five 606 The collaborative arrangements may one not Licenses of Intellectual Property: not Research and Development Service: Milestone Payments: not not Royalties:
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value measurements The Company applies ASC 820, Fair Value Measurements and Disclosures 820” 820 ASC 820 three • Level 1—Observable • Level 2—Other • Level 3—Unobservable no ASC 820 three 1 2 3 Financial instruments of the Company primarily include cash and cash equivalents, short-term investments, accounts payable, contingently redeemable noncontrolling interests, forward liability and loans. The contingently redeemable noncontrolling interests were initially recorded at issuance price net of issuance costs. The Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying value of the contingently redeemable noncontrolling interests to equal the redemption value at the end of each reporting period. The Company measures its available-for-sale debt securities, trading debt securities and forward liability at fair value on a recurring basis. As of December 31, 2020 September 30, 2021, As of December 31, 2020, 2 Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 September 30, 2021 Fair value measurement Recurring fair value measurement Total Fair Value Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total gains $ $ $ $ $ As of December 31, 2020 (audited) Liabilities: Forward liability (Note 3) 278 - - 278 - As of September 30, 2021 (unaudited) Assets: Available-for-sale debt securities 1,645 - 1,645 - - Trading debt securities 12,521 - 12,521 - 105 Total assets measured at fair value 14,166 - 14,166 - 105 Liabilities Forward liability (Note 3) 278 - - 278 - Total liabilities measured at fair value 278 - - 278 - The Company determined the fair value of the forward liability with the assistance of an independent third December 31, 2020 September 30, 2021 three nine September 30, 2021, not The following table represents the assumptions used to estimate the fair value of the forward liability: Valuation technique Unobservable inputs Range Forward liability Discounted cash flow Fair value of underlying security 2.65 The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Forward liability $ Balance as of December 31, 2020 (audited) 278 Gains or losses from changes in fair value - Balance as of September 30, 2021 (unaudited) 278

Note 1 - Nature of the Busine_2

Note 1 - Nature of the Business and Basis of Preparation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Subsidiaries [Table Text Block]	Percentage of Date of ownership by the Principal Name of company Place of incorporation incorporation Company Activities BeyondSpring Pharmaceuticals Inc. Delaware, (“BeyondSpring US ”) United States of America (“U.S.”) June 18, 2013 100% Clinical trial activities BeyondSpring Ltd. The British Virgin Islands (“BVI”) December 3, 2014 100% Holding company BeyondSpring (HK) Limited (“BeyondSpring HK”) Hong Kong January 13, 2015 100% Holding company Wanchun Biotechnology Limited (“BVI Biotech”) BVI April 1, 2015 100% Holding company Wanchun Biotechnology (Shenzhen) Ltd. The People’s Republic of China (“Wanchun Shenzhen”) (“PRC”) April 23, 2015 100% Holding company Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) PRC May 6, 2015 58.0% Clinical trial activities BeyondSpring Pharmaceuticals Australia PTY Ltd. (“BeyondSpring Australia”) Australia March 3, 2016 100% Clinical trial activities Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”) PRC May 21, 2018 58.0% Holding company SEED Therapeutics Inc. (“SEED”) BVI June 25, 2019 59.0% Pre-clinical development activities SEED Technology Limited (“SEED Technology”) BVI December 9, 2019 58.0% Holding company SEED Therapeutics US, Inc. (“SEED US”) Delaware, U.S. November 25, 2020 59.0% Pre-clinical development activities

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair value measurement Recurring fair value measurement Total Fair Value Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total gains $ $ $ $ $ As of December 31, 2020 (audited) Liabilities: Forward liability (Note 3) 278 - - 278 - As of September 30, 2021 (unaudited) Assets: Available-for-sale debt securities 1,645 - 1,645 - - Trading debt securities 12,521 - 12,521 - 105 Total assets measured at fair value 14,166 - 14,166 - 105 Liabilities Forward liability (Note 3) 278 - - 278 - Total liabilities measured at fair value 278 - - 278 -
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]	Valuation technique Unobservable inputs Range Forward liability Discounted cash flow Fair value of underlying security 2.65
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Forward liability $ Balance as of December 31, 2020 (audited) 278 Gains or losses from changes in fair value - Balance as of September 30, 2021 (unaudited) 278

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2020 September 30, 2021 $ $ (Unaudited) Office equipment 181 213 Laboratory equipment 121 127 Motor vehicles 24 24 Leasehold improvements 116 117 442 481 Less: accumulated depreciation (258 ) (312 ) Property and equipment, net 184 169

Note 5 - Loans (Tables)

Note 5 - Loans (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	Maturity dates Amount $ (Unaudited) Year ending December 31, 2021 - Year ending December 31, 2022 1,552 Total 1,552

Note 8 - Equity (Tables)

Note 8 - Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Stockholders Equity [Table Text Block]	BeyondSpring Inc. s shareholders Accumulated Additional other Non Ordinary share paid-in Accumulated comprehensive controlling Total Shares Amount capital deficit (loss) gain Subtotal interests equity $ $ $ $ $ $ $ Balances at January 1, 2021 (audited) 39,141,913 4 366,451 (277,818 ) (297 ) 88,340 (1,715 ) 86,625 Share-based compensation 12,248 - 5,143 - - 5,143 20 5,163 Forfeited restricted shares (40,679 ) - (310 ) - - (310 ) - (310 ) Exercise of options 28,771 - 83 - - 83 - 83 Accretion of contingently redeemable noncontrolling interest - - (158 ) - - (158 ) - (158 ) Foreign currency translation adjustment loss - - - - (101 ) (101 ) (15 ) (116 ) Net loss - - - (54,666 ) - (54,666 ) (2,814 ) (57,480 ) Balances at September 30, 2021 (unaudited) 39,142,253 4 371,209 (332,484 ) (398 ) 38,331 (4,524 ) 33,807 Balances at January 1, 2020 (audited) 27,885,613 3 246,979 (216,845 ) 140 30,277 854 31,131 Issuance of ordinary shares 2,613,590 - 31,395 - - 31,395 - 31,395 Share-based compensation 17,198 - 5,936 - - 5,936 132 6,068 Foreign currency translation adjustment loss - - - - (187 ) (187 ) (39 ) (226 ) Net loss - - - (43,377 ) - (43,377 ) (2,068 ) (45,445 ) Balances at September 30, 2020 (unaudited) 30,516,401 3 284,310 (260,222 ) (47 ) 24,044 (1,121 ) 22,923

Note 11 - Net Loss Per Share (T

Note 11 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three months ended September 30, Nine months ended September 30, 2020 2021 2020 2021 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Numerator: Net loss attributable to BeyondSpring Inc.—basic and diluted $ (14,540 ) $ (18,370 ) $ (43,377 ) $ (54,666 ) Denominator: Weighted average number of ordinary shares outstanding—basic and diluted 30,303,093 39,024,892 28,658,215 39,013,526 Net loss per share —basic and diluted $ (0.48 ) $ (0.47 ) $ (1.51 ) $ (1.40 )

Note 12 - Supplemental Balanc_2

Note 12 - Supplemental Balance Sheet Information (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Other Current Liabilities [Table Text Block]	As of December 31, As of September 30, 2020 2021 $ $ (Unaudited) Compensation related 2,222 2,376 Professional services 373 99 Income tax payable - 2,588 Other taxes related 857 358 Forward liability 278 278 Others 76 69 Total 3,806 5,768

Note 13 - Share-based Compens_2

Note 13 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three months ended September 30, Nine months ended September 30, 2020 2021 2020 2021 $ $ $ $ (Unaudited) (Unaudited) (Unaudited) (Unaudited) Research and development 257 732 4,008 1,639 General and administrative 1,519 1,010 2,074 3,651 Total 1,776 1,742 6,082 5,290

Note 14 - Contingently Redeem_2

Note 14 - Contingently Redeemable Noncontrolling Interests (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Redeemable Noncontrolling Interest [Table Text Block]	Contingently redeemable noncontrolling interests $ Balance as of December 31, 2020 (audited) 5,196 Accretion to redemption value 158 Balance as of September 30, 2021 (unaudited) 5,354

Note 1 - Nature of the Busine_3

Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details)	Sep. 30, 2021
BeyondSpring Pharmaceuticals Inc. [Member]
Equity method investment, ownership percentage	100.00%
BeyondSpring Ltd. [Member]
Equity method investment, ownership percentage	100.00%
BeyondSpring HK Limited [Member]
Equity method investment, ownership percentage	100.00%
Wanchun Biotechnology Limited [Member]
Equity method investment, ownership percentage	100.00%
Wanchun Biotechnology (Shenzhen) Ltd. [Member]
Equity method investment, ownership percentage	100.00%
Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) [Member]
Equity method investment, ownership percentage	58.00%
BeyondSpring Pharmaceuticals Australia PTY Ltd. (“BeyondSpring Australia”) [Member]
Equity method investment, ownership percentage	100.00%
Beijing Wanchun Pharmaceutical Technology Ltd. [Member]
Equity method investment, ownership percentage	58.00%
SEED Therapeutics1 Inc. [Member]
Equity method investment, ownership percentage	59.00%
SEED Technology Limited [Member]
Equity method investment, ownership percentage	58.00%
SEED Therapeutics US, Inc. [Member]
Equity method investment, ownership percentage	59.00%

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total	$ (20,143)	$ (15,184)	$ (57,480)	$ (45,445)
Retained Earnings (Accumulated Deficit), Ending Balance	(332,484)		(332,484)		$ (277,818)
Net Cash Provided by (Used in) Operating Activities, Total			(30,324)	$ (36,783)
Net Current Assets	76,111		76,111
Cash, Cash Equivalents, and Short-term Investments, Total	91,600		91,600
Debt Securities, Trading, Unrealized Gain	105		105
Debt Securities, Available-for-sale, Amortized Cost, Total	1,645		1,645
Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance	0		0
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total			0
Contract with Customer, Asset, after Allowance for Credit Loss, Total	0		0
Long-term Debt, Excluding Current Maturities, Total	$ 0		0		2,167
Long-term Debt, Fair Value					$ 2,136
Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total			$ 0

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Total assets measured at fair value, gains (losses)	$ 105	$ 0
Fair Value, Recurring [Member] | Reported Value Measurement [Member]
Forward liability (Note 3)	278		$ 278
Available-for-sale debt securities	1,645
Trading debt securities	12,521
Total assets measured at fair value	14,166
Total liabilities measured at fair value	278
Fair Value, Recurring [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Forward liability (Note 3)	0		0
Available-for-sale debt securities	0
Trading debt securities	0
Total assets measured at fair value	0
Total liabilities measured at fair value	0
Fair Value, Recurring [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Forward liability (Note 3)	0		0
Available-for-sale debt securities	1,645
Trading debt securities	12,521
Total assets measured at fair value	14,166
Total liabilities measured at fair value	0
Fair Value, Recurring [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Forward liability (Note 3)	278		$ 278
Available-for-sale debt securities	0
Available-for-sale debt securities, gains (losses)	0
Trading debt securities	0
Trading debt securities, gains (losses)	105
Total assets measured at fair value	0
Total assets measured at fair value, gains (losses)	105
Total liabilities measured at fair value	$ 278

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Assumptions Used to Estimate the Fair Value of the Forward Liability (Details)	Sep. 30, 2021
Fair Value of Underlying Security [Member] | Valuation, Income Approach [Member]
Forward liability	2.65

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Reconciliation of Changes in Fair Value (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Balance	$ 278
Gains or losses from changes in fair value	0
Balance	$ 278

Note 3 - Collaboration Revenue

Note 3 - Collaboration Revenue (Details Textual) $ / shares in Units, ¥ in Thousands, $ in Thousands	Nov. 12, 2020$ / sharesshares	Nov. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Nov. 12, 2022$ / sharesshares	Sep. 30, 2021CNY (¥)
Revenue from Contract with Customer, Including Assessed Tax			$ 337	$ 0	$ 1,013	$ 0
Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) [Member] | Jiangsu Hengrui Pharmaceuticals Co., Ltd. [Member]
Collaboration Agreement, Upfront Cash Payment			31,039		31,039			¥ 200,000
Research Collaboration and License Agreement with Eli Lilly [Member] | Series A-2 Preferred Shares [Member]
Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value			5,267		5,267
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]
Collaborative Arrangement, Upfront Cash Payment		$ 10,000
Derivative Liability, Total			278		278
Revenue from Contract with Customer, Including Assessed Tax			337		1,013
Collaboration Agreement,, Maximum Regulatory Development Milestones to be Received			108,638		108,638			700,000
Collaboration Agreement, Maximum Commercial Milestones to be Received			62,079		62,079			¥ 400,000
Revenue from Contract with Customer, Excluding Assessed Tax, Total			$ 0		$ 0
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Convertible Preferred Shares [Member]
Stock Issued for Transfer of Assets, Shares (in shares) | shares	9,631,941
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Preferred Shares [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	1,194,030
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-2 Preferred Shares [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	1,990,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 2.5125
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Additional Series A-2 Preferred Shares [Member] | Forecast [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares							1,990,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares							$ 2.5125
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Maximum [Member]
Collaborative Arrangement, Equity Investment		$ 780,000

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Depreciation, Total	$ 17	$ 22	$ 54	$ 54

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, plant, and equipment, gross	$ 481	$ 442
Less: accumulated depreciation	(312)	(258)
Property and equipment, net	169	184
Office Equipment [Member]
Property, plant, and equipment, gross	213	181
Laboratory Equipment [Member]
Property, plant, and equipment, gross	127	121
Automobiles [Member]
Property, plant, and equipment, gross	24	24
Leasehold Improvements [Member]
Property, plant, and equipment, gross	$ 117	$ 116

Note 5 - Loans (Details Textual

Note 5 - Loans (Details Textual) $ in Thousands, ¥ in Millions	May 03, 2020USD ($)	Mar. 28, 2019USD ($)	Jul. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Mar. 28, 2019CNY (¥)
Long-term Debt, Total				$ 1,552
Gain (Loss) on Extinguishment of Debt, Total				$ 635	$ 0
Term Loan [Member] | China Construction Bank [Member]
Debt Instrument, Term (Year)		3 years
Long-term Debt, Total		$ 1,493				¥ 10
Debt Instrument, Interest Rate, Stated Percentage				5.25%
Paycheck Protection Program CARES Act [Member]
Debt Instrument, Term (Year)	2 years
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Proceeds from Issuance of Long-term Debt, Total	$ 635
Paycheck Protection Program CARES Act [Member] | Other Nonoperating Income (Expense) [Member]
Gain (Loss) on Extinguishment of Debt, Total			$ 635

Note 5 - Loans - Schedule of Ma

Note 5 - Loans - Schedule of Maturities (Details) $ in Thousands	Sep. 30, 2021USD ($)
Year ending December 31, 2021	$ 0
Year ending December 31, 2022	1,552
Total	$ 1,552

Note 6 - Related Party Transa_2

Note 6 - Related Party Transactions (Details Textual) - 9 months ended Sep. 30, 2020 ¥ in Thousands, $ in Thousands	USD ($)	CNY (¥)
Dalian Wanchun Biotechnology Co., Ltd. [Member]
Proceeds from Short-term Debt, Total	$ 32	¥ 230

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Expense (Benefit), Total	$ 2,588	$ 0	$ 2,588	$ 0
Effective Income Tax Rate Reconciliation, Percent, Total			(4.70%)	0.00%

Note 8 - Equity - Schedule of S

Note 8 - Equity - Schedule of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Balances			$ 86,625	$ 31,131
Share-based compensation			5,163	6,068
Forfeited restricted shares			(310)
Exercise of options			83
Accretion of contingently redeemable noncontrolling interest			(158)
Foreign currency translation adjustment loss	$ (41)	$ (277)	(116)	(226)
Net loss	(20,143)	(15,184)	(57,480)	(45,445)
Issuance of ordinary shares				31,395
Balances	$ 33,807	$ 22,923	$ 33,807	$ 22,923
Common Stock [Member]
Balances (in shares)			39,141,913	27,885,613
Balances			$ 4	$ 3
Share-based compensation (in shares)			12,248	17,198
Share-based compensation			$ 0	$ 0
Forfeited restricted shares (in shares)			(40,679)
Forfeited restricted shares			$ 0
Exercise of options (in shares)			28,771
Exercise of options			$ 0
Accretion of contingently redeemable noncontrolling interest			0
Foreign currency translation adjustment loss			0	0
Net loss			$ 0	$ 0
Issuance of ordinary shares (in shares)				2,613,590
Issuance of ordinary shares				$ 0
Balances (in shares)	39,142,253	30,516,401	39,142,253	30,516,401
Balances	$ 4	$ 3	$ 4	$ 3
Additional Paid-in Capital [Member]
Balances			366,451	246,979
Share-based compensation			5,143	5,936
Forfeited restricted shares			(310)
Exercise of options			83
Accretion of contingently redeemable noncontrolling interest			(158)
Foreign currency translation adjustment loss			0	0
Net loss			0	0
Issuance of ordinary shares				31,395
Balances	371,209	284,310	371,209	284,310
Retained Earnings [Member]
Balances			(277,818)	(216,845)
Share-based compensation			0	0
Forfeited restricted shares			0
Exercise of options			0
Accretion of contingently redeemable noncontrolling interest			0
Foreign currency translation adjustment loss			0	0
Net loss			(54,666)	(43,377)
Issuance of ordinary shares				0
Balances	(332,484)	(260,222)	(332,484)	(260,222)
AOCI Attributable to Parent [Member]
Balances			(297)	140
Share-based compensation			0	0
Forfeited restricted shares			0
Exercise of options			0
Accretion of contingently redeemable noncontrolling interest			0
Foreign currency translation adjustment loss			(101)	(187)
Net loss			0	0
Issuance of ordinary shares				0
Balances	(398)	(47)	(398)	(47)
Parent [Member]
Balances			88,340	30,277
Share-based compensation			5,143	5,936
Forfeited restricted shares			(310)
Exercise of options			83
Accretion of contingently redeemable noncontrolling interest			(158)
Foreign currency translation adjustment loss			(101)	(187)
Net loss			(54,666)	(43,377)
Issuance of ordinary shares				31,395
Balances	38,331	24,044	38,331	24,044
Noncontrolling Interest [Member]
Balances			(1,715)	854
Share-based compensation			20	132
Forfeited restricted shares			0
Exercise of options			0
Accretion of contingently redeemable noncontrolling interest			0
Foreign currency translation adjustment loss			(15)	(39)
Net loss			(2,814)	(2,068)
Issuance of ordinary shares				0
Balances	$ (4,524)	$ (1,121)	$ (4,524)	$ (1,121)

Note 9 - Restricted Net Assets

Note 9 - Restricted Net Assets (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Restricted Net Assets	$ 0	$ 0

Note 10 - Employee Defined Co_2

Note 10 - Employee Defined Contribution Plan (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Defined Contribution Plan, Cost	$ 86	$ 34	$ 212	$ 81

Note 11 - Net Loss Per Share -

Note 11 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net loss attributable to ordinary shareholders	$ (18,370)	$ (14,540)	$ (54,666)	$ (43,377)
Weighted average number of ordinary shares outstanding—basic and diluted (in shares)	39,024,892	30,303,093	39,013,526	28,658,215
Net loss per share —basic and diluted (in dollars per share)	$ (0.47)	$ (0.48)	$ (1.40)	$ (1.51)

Note 12 - Supplemental Balanc_3

Note 12 - Supplemental Balance Sheet Information - Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Compensation related	$ 2,376	$ 2,222
Professional services	99	373
Income tax payable	2,588	0
Other taxes related	358	857
Forward liability	278	278
Others	69	76
Total	$ 5,768	$ 3,806

Note 13 - Share-based Compens_3

Note 13 - Share-based Compensation (Details Textual) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	153,000	1,054,499
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	6,699	8,125

Note 13 - Share-based Compens_4

Note 13 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Allocated Share-based Compensation Expense	$ 1,742	$ 1,776	$ 5,290	$ 6,082
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	732	257	1,639	4,008
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	$ 1,010	$ 1,519	$ 3,651	$ 2,074

Note 14 - Contingently Redeem_3

Note 14 - Contingently Redeemable Noncontrolling Interests (Details Textual) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2021USD ($)$ / shares
Temporary Equity, Accretion to Redemption Value		$ 158
Series A-2 Preferred Shares [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]
Temporary Equity, Stock Issued During Period, Value, New Issues		$ 0
Share Price (in dollars per share) | $ / shares	$ 0.50	$ 0.50
Convertible Instrument, Conversion Price (in dollars per share) | $ / shares	$ 2.5125	$ 2.5125
Temporary Equity, Accretion to Redemption Value	$ 96	$ 158

Note 14 - Contingently Redeem_4

Note 14 - Contingently Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests, Net of Issuance Costs (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Balance	$ 5,196
Accretion to redemption value	158
Balance	$ 5,354